SCM
NKTR icon

Stonepine Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Stonepine Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$2.11M – 96
2025
Q4 		$2.11M Buy
+50,000
New +$2.8M 1.54% 22

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Stonepine Capital Management's NKTR Position: Q1 2026 in Review

Stonepine Capital Management held its Nektar Therapeutics (NKTR) position steady in Q1 2026 at 85,000 shares worth $6.12M. The position accounts for 2.45% of the portfolio, ranked #9.

Stonepine Capital Management first reported a position in NKTR in Q1 2024 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Stonepine Capital Management held 85,000 shares of Nektar Therapeutics worth $6.12M as of Q1 2026.
  • Stonepine Capital Management left its Nektar Therapeutics share count unchanged in Q1 2026.
  • Nektar Therapeutics made up 2.45% of Stonepine Capital Management's portfolio in Q1 2026, its #9 holding.
  • Stonepine Capital Management first reported a position in Nektar Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.